1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Demographics of the study population and the number of GBCA administrations
Healthy Controls Linear MS Group Mixed MS Group Macrocyclic MS Group
Participants (No.) 21 11 59 15
Male/female ratio 10:11 3:8 18:41 4:11
Age (mean) (yr) 35.9 ± 13.8 51.0 ± 10.7 43.8 ± 10.3 37.4 ± 13.7
MS duration (mean) (yr) NA 19.8 ± 9.3 12.9 ± 8.1 5.1 ± 6.0
MS subtype, RR/SP/PP NA 5/6/0 39/17/3 14/1/0
EDSS score (median) (range) NA 2.5 (0–6); n = 11 2 (08.5); n = 54 2 (1–4); n = 13
SDMT score (median) (range) NA −0.19 (−1.47–0.84); n = 5 −1.1 (−3.9–1.4); n = 36 −1.3 (−4.3–0.51); n = 12
Verbal fluency test score (median) (range) NA 0.74 (−1.82–.36); n = 4 −0.24 (−2.47–2.17); n= 17 −1.32 (−2.94–.04); n = 6
MS lesion volume (median ± interquartile range) (mL) NA 5.1 ± 10.1 3.1 ± 9.2 2.4 ± 4.2
Brain parenchymal fraction (%) 88.0 ± 2.4 79.6 ± 4.9 82.7 ± 5.9 84.6 ± 5.0
Linear GBCA administrations (No.) (median) (range) 0 3 (1–7) 4 (1–19) 0 (0)
Macrocyclic GBCA administrations (No.) (median) (range) 0 0 2 (1–4) 3 (1–6)
Time since last GBCA administration (median) (range) (mo) NA 52 (24–172) 12 (3–91) 7 (3–14)
Note:—PP indicates primary-progressive; RR, relapsing-remitting; SP, secondary-progressive; NA, not applicable.
a Numbers are given as means unless otherwise specified.